P0376 : Stratification of hepatocellular carcinoma. The prognostic score NIACE, an additional aid to the Barcelona Clinic Liver Cancer (BCLC) staging system? Multicenter study

Adhoute, Xavier; Pénaranda, Guillaume; Blanc, Jean Frédéric; Edeline, Julien; Naudé, Sébastien; Perrier, H.; Monnet, O.; Castellani, Paul; Oulès, Valérie; Bayle, Olivier; Conroy, Guillaume; Benali, Souâd; Lefolgoc, G.; Pol, Bernard; Bronowicki, Jean–Pierre; Raoul, Jean-Luc; Bourlière, Marc

doi:10.1016/s0168-8278(15)30589-4

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other scores, independent of the BCLC system[ 7 , 18 , 19 ] or additional to the BCLC system[ 20 , 21 ] have been proposed in recent years. NIACE score (tumor Nodularity, Infiltrative nature of the tumor, serum Alpha-fetoprotein level, Child-Pugh stage, ECOG performance status)[ 22 ] determines sub-groups of different survival prognosis irrespective of the BCLC stage[ 23 ], or HCC treatment modalities[ 24 ]. This score has been validated either in European or Asian cohorts[ 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Adhoute

Pénaranda

Raoul

et al. 2017

WJG

View full text Add to dashboard Cite

AIMTo compare the performances of the Barcelona clinic liver cancer (BCLC) nomogram and others systems (BCLC, HKLC, CLIP, NIACE) for survival prediction in a large hepatocellular carcinoma (HCC) French cohort.METHODSData were collected retrospectively from 01/2007 to 12/2013 in five French centers. Newly diagnosed HCC patients were analyzed. The discriminatory ability, homogeneity ability, prognostic stratification ability Akaike information criterion (AIC) and C-index were compared among scoring systems.RESULTSThe cohort included 1102 patients, mostly men, median age 68 [60-74] years with cirrhosis (81%), child-Pugh A (73%), alcohol-related (41%), HCV-related (27%). HCC were multinodular (59%) and vascular invasion was present in 41% of cases. At time of HCC diagnosis BCLC stages were A (17%), B (16%), C (60%) and D (7%). First line HCC treatment was curative in 23.5%, palliative in 59.5%, BSC in 17% of our population. Median OS was 10.8 mo [4.9-28.0]. Each system distinguished different survival prognosis groups (P < 0.0001). The nomogram had the highest discriminatory ability, the highest C-index value. NIACE score had the lowest AIC value. The nomogram distinguished sixteen different prognosis groups. By classifying unifocal large HCC into tumor burden 1, the nomogram was less powerful.CONCLUSIONIn this French cohort, the BCLC nomogram and the NIACE score provided the best prognostic information, but the NIACE could even help treatment strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Adhoute

Pénaranda

Raoul

et al. 2017

WJG

View full text Add to dashboard Cite

show abstract

“…In a multicenter cohort study, ALBI grade was highly concordant with CP‐based classification ( n = 3696) 29,30 . The overall prognostic performance of ALBI grading is particularly good in intermediate‐ and advanced‐stage disease 31–36 . (Figure 1).…”

Section: Introductionmentioning

confidence: 84%

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 10 The NIACE score predicted HCC treated with Sorafenib and included this indicator and also suggested that ≥3 tumor nodules were a prognostic factor for survival. 34 …”

Section: Discussionmentioning

confidence: 99%

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma

Ding

Liu

et al. 2023

The Oncologist

View full text Add to dashboard Cite

Background Lenvatinib is a first-line agent for advanced hepatocellular carcinoma (HCC), but individual responses to treatment are highly heterogeneous. The aim of this study was to investigate the clinical parameters that influence the efficacy of Lenvatinib and to develop a prognostic model. Methods We retrospectively enrolled 333 Lenvatinib-treated patients with HCC with a median age of 57 years. Two hundred nd sixty-three of these patients had BCLC (2022) stage C. The median overall survival (mOS) time within the cohort was 12.1 months, and the median progression-free survival (mPFS) time was 4.7 months. Univariate Cox regression, best subset regression, and Lasso regression were used to screen primary variables for possible contribution to OS, multivariate Cox analysis was used to fit selected models, and the final model was selected using the maximum area under the curve (AUC) and minimum AIC. Receiver operating curves (ROC), calibration curves, and decision curve analysis were plotted to assess model performance, and 5-fold cross-validation was performed for internal validation. X-tile software was used to select the best cutoff points and to divide the study cohort into 3 different risk groups. Results Seven variables were included in the final model: BCLC stage, prior transarterial chemoembolization and immunotherapy history, tumor number, prognostic nutritional index, log (alpha-fetoprotein), and log (platelet-to-lymphocyte ratio). We named this final model the “multivariate prognostic model for Lenvatinib” (MPML), and a nomogram was constructed to predict the probability of survival at 6, 9, and 12 months. The MPML had good discrimination, calibration, and applicability. Cross-validation showed mean AUC values of 0.7779, 0.7738, and 0.7871 at 6, 9, and 12 months, respectively. According to nomogram points, mOS time was 21.57, 8.70, and 5.37 months in the low, medium, and high-risk groups, respectively (P < .001), and these differences were also observed in the PFS survival curve (P < .001). Conclusions The MPML stratified patients according to baseline clinical characteristics had a strong performance in predicting Lenvatinib efficacy and has the potential for use as an auxiliary clinical tool for individualized decision-making.

show abstract

P0376 : Stratification of hepatocellular carcinoma. The prognostic score NIACE, an additional aid to the Barcelona Clinic Liver Cancer (BCLC) staging system? Multicenter study

Cited by 6 publications

References 0 publications

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma

Contact Info

Product

Resources

About